1. The future of biologics: Applications for food allergy
Rebecca N. Bauer, PhD, Monali Manohar, PhD, Anne Marie Singh, MD, David C. Jay, PhD, Kari C. Nadeau, MD, PhD, FAAAAI 
Journal of Allergy and Clinical Immunology 
Volume 135, Issue 2, Pages (February 2015)
DOI: /j.jaci
Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2. Fig 1
Oral tolerance. In patients with oral tolerance, antigen is recognized by the immune system but does not induce adverse immune reactions. DCs sample luminal contents, recognize antigen, and traffic to lymph nodes. Activated tolerogenic DCs and macrophages secrete regulatory mediators, such as IL-10, TGF-β, and retinoic acid (RA). Tolerogenic DCs migrate to the lymph nodes to present antigens to naive T lymphocytes (TH0) and promote differentiation of Treg cells. Treg cells secrete IL-10 and reduce effector CD4+ and CD8+ T-cell responses.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3. Fig 2
Breakdown of tolerance. Allergy is associated with a breakdown in tolerance that promotes antigen sensitization. Increased EC permeability permits access of allergens to the underlying mucosa. ECs produce cytokines, such as TSLP, IL-33, and IL-25, that skew DC phenotype, activate ILCs, and promote type 2 (TH2) immunity. DCs recognize food antigen and migrate to the lymph node, where they present allergens to naive T lymphocytes (TH0) in the presence of TH2-polarizing mediators (eg, IL-4) to promote the development of TH2 lymphocytes. TH2 lymphocytes secrete additional type 2 cytokines (IL-4, IL-5, and IL-13) and promote B-cell isotype switching and IgE production. IgE binds to FcεRI/II receptors expressed by cells, such as mast cells and basophils, to promote inflammatory allergic responses.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4. Fig 3
Early- and late-phase anaphylaxis. Anaphylactic reactions to allergens occur as an early and a late phase. In the early phase IgE-allergen complexes are recognized by FcεRI/II expressed by cells, such as mast cells and basophils. Activation through FcεRI/II promotes the release of preformed mediators, such as PAF, histamine, cytokines and chemokines, leukotrienes, and proteases. These mediators induce immediate anaphylactic symptoms, including vasodilation, vascular permeability, and bronchoconstriction, and promote leukocyte recruitment from circulation. During the late-phase reaction, recruited leukocytes, including basophils, eosinophils, T lymphocytes, and monocytes/macrophages, produce inflammatory cytokines, proteases, and cytotoxic mediators that can damage tissue and induce anaphylactic symptoms.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions